{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-005554","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.550724+00:00","generated_at":"2026-05-23T05:48:48.056265+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Director Mark Stolper to leave board at 2025 annual meeting; board rebalanced","bullets":["Mark D. Stolper notified Board he will not stand for re-election at 2025 annual meeting; departure not due to any disagreement.","Stolper will serve until election of directors at 2025 Annual Meeting, then expected to consult through Dec 31, 2026.","Board decreased authorized directors from 10 to 9, effective upon Stolper's departure.","Rita A. Karachun reclassified from Class II to Class I; Michael Ryan from Class III to Class II to balance board classes.","Board now has three Class I, four Class II, and three Class III directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-005554","json":"https://secwatch.observer/filing/0001558370-25-005554.json","markdown":"https://secwatch.observer/filing/0001558370-25-005554.md","text":"https://secwatch.observer/filing/0001558370-25-005554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/0001558370-25-005554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/chrs-20250422x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:48:48.056265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6eb00dd94e","claim":"Mark D. Stolper departed as Director at Coherus Oncology, Inc..","evidence_excerpt":"On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025005554/0001558370-25-005554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}